Phase 2 Breast Cancer Trial, Recruiting NCT06327490 Sponsor: University of Florida Condition: Breast Cancer
Back to Breast Cancer

Phase 2 Breast Cancer Trial, Recruiting

NCT06327490
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Adults aged 18 or older
  • People who are having underarm (axillary) lymph node removal surgery, with or without lymphatic reconstruction, as part of their breast cancer diagnosis and treatment
  • People who have had a special dye-based imaging procedure (called ICG lymphatic mapping) done before their lymph node removal surgery
  • People diagnosed with breast cancer ranging from very early stage to more advanced stages (stage Tis through T4, with or without lymph node involvement, but without distant spread — confirm with trial site if unsure of your stage)
  • People who are generally well enough to carry out light daily activities (a level of physical fitness measured by a standard medical scale called ECOG 0–1)
  • People who have only one active cancer at the time of joining the trial (people with a past or additional cancer may still be considered, but only if the treating doctor and study leader agree it would not affect the trial)
  • People who have given written agreement to take part and follow all study procedures
  • People who could become pregnant must have a negative pregnancy test before joining and must use a reliable method of contraception throughout the study
  • People who have had a physical therapy assessment before their lymph node removal surgery
  • People who received chemotherapy before surgery (neoadjuvant chemotherapy) must have had a physical therapy lymphedema assessment after completing chemotherapy and before surgery

Who may not be able to join:

  • People with a history of breast cancer (including non-invasive types) on the same side being treated
  • People who have previously had surgery in the underarm area on the same side, such as lymph node removal or treatment for certain skin conditions affecting that area
  • People with a history of, or a current diagnosis of, breast cancer on the opposite side (both breasts affected)
  • People who have had, or are planned to have, underarm surgery on the opposite side
  • People with a history of, or current, cancer affecting the arm on the same side as the breast being treated (for example, skin cancer on that arm)
  • People who have had lymphedema (swelling caused by lymph fluid build-up) or lymphatic flow problems in either arm, or who are found to have lymphatic problems at their pre-surgery appointment
  • People with a history of blood clots in the upper arm or infections of the lymph vessels or skin (such as lymphangitis or cellulitis)
  • People with a history of heart failure or significant heart disease, including those with certain types of pacemakers that are not compatible with a body fluid measurement test used in this study
  • People with evidence of serious liver disease or liver failure
  • People from whom fewer than 10 lymph nodes were removed (or fewer than 8 if they received chemotherapy before surgery), including any nodes removed during a sentinel lymph node biopsy
  • People for whom there is no detailed surgical record of what was found and done during the lymph node removal operation
  • People who are confirmed to be pregnant or breastfeeding
  • People with any other medical condition, test result, or finding that the treating doctor believes could interfere with the study or pose a significant health risk
  • People who are prisoners, involuntarily detained, or held in a facility for psychiatric or medical treatment against their will

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 20 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Lisa Spiguel, MD, University of Florida

Phone: 352-273-3650

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Registry
ClinicalTrials.gov
Start date
15 October 2024
Est. completion
1 June 2028

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Subject compliance

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 20 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov